Abstract
Histone deacetylases (HDACs) are a family of conserved metalloproteases which play a key role in the development of cancer. They can be divided into 18 subtypes according to their structural diversity. Histone deacetylase inhibitors are considered as potential anti-cancer agents and a lot of pan-HDAC inhibitors have entered clinical trials. Selective HDAC inhibitors targeting only one member or one class subtype are less exploited at present and regarded less toxic as well as more tolerable than pan-HDAC inhibitors. Certain structural modifications or new moieties may help to acquire isoform selectivity. In this review, we will focus on each member of HDACs and selective HDAC inhibitors as well as the relationship between structure and selectivity.
Keywords: HDAC, Histone deacetylase inhibitors, Selectivity, Anti-cancer agents, aminobenzamides, cyclic peptides, yeast HDACs, C-terminus, bone homeostasis, Sirtuins
Anti-Cancer Agents in Medicinal Chemistry
Title: Selective Histone Deacetylase Inhibitors
Volume: 12 Issue: 3
Author(s): Huili Pan, Jiangying Cao and Wenfang Xu
Affiliation:
Keywords: HDAC, Histone deacetylase inhibitors, Selectivity, Anti-cancer agents, aminobenzamides, cyclic peptides, yeast HDACs, C-terminus, bone homeostasis, Sirtuins
Abstract: Histone deacetylases (HDACs) are a family of conserved metalloproteases which play a key role in the development of cancer. They can be divided into 18 subtypes according to their structural diversity. Histone deacetylase inhibitors are considered as potential anti-cancer agents and a lot of pan-HDAC inhibitors have entered clinical trials. Selective HDAC inhibitors targeting only one member or one class subtype are less exploited at present and regarded less toxic as well as more tolerable than pan-HDAC inhibitors. Certain structural modifications or new moieties may help to acquire isoform selectivity. In this review, we will focus on each member of HDACs and selective HDAC inhibitors as well as the relationship between structure and selectivity.
Export Options
About this article
Cite this article as:
Pan Huili, Cao Jiangying and Xu Wenfang, Selective Histone Deacetylase Inhibitors, Anti-Cancer Agents in Medicinal Chemistry 2012; 12 (3) . https://dx.doi.org/10.2174/187152012800228814
DOI https://dx.doi.org/10.2174/187152012800228814 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Alternative Polyadenylation and Its Impact on Cellular Processes
MicroRNA Nanocarriers Made from Non-Ionic Surfactants or Natural Polymers for Pulmonary Drug Delivery
Current Pharmaceutical Design The Anti-Breast Cancer Potential of Bis-Isatin Scaffolds
Current Topics in Medicinal Chemistry Targeted Photodynamic Therapy (PDT) of Lung Cancer with Biotinylated Silicon (IV) Phthalocyanine
Current Pharmaceutical Biotechnology Ethanolic Extract of Berberis Vulgaris Fruits Inhibits the Proliferation of MCF-7 Breast Cancer Cell Line Through Induction of Apoptosis
Infectious Disorders - Drug Targets On the Physiological Role of Cytosolic 5’-nucleotidase II (cN-II): Pathological and Therapeutical Implications.
Current Medicinal Chemistry Targeted Therapy Towards Cancer-A Perspective
Anti-Cancer Agents in Medicinal Chemistry Cytochrome P450 Retinoic Acid 4-Hydroxylase Inhibitors: Potential Agents for Cancer Therapy
Mini-Reviews in Medicinal Chemistry Cellular Senescence in the Development and Treatment of Cancer
Current Pharmaceutical Design Influence of the Bystander Effect on HSV-tk / GCV Gene Therapy. A Review.
Current Gene Therapy ADAM Metalloproteinases as Potential Drug Targets
Current Medicinal Chemistry Role of NF-κB and NF-κB-regulated Gene Products in Chemoresistance and Radioresistance
Current Cancer Therapy Reviews Current Therapeutic Paradigms in Glioblastoma
Reviews on Recent Clinical Trials Lamellarins, from A to Z: A Family of Anticancer Marine Pyrrole Alkaloids
Current Medicinal Chemistry - Anti-Cancer Agents Emerging Role of the Ubiquitin-proteasome System as Drug Targets
Current Pharmaceutical Design Therapeutical Approaches of Vasoactive Intestinal Peptide as a Pleiotropic Immunomodulator
Current Pharmaceutical Design Mechanisms of Interferon Mediated Anti-Viral Resistance
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Molecular Targets of Ovarian Carcinomas with Acquired Resistance to Platinum/Taxane Chemotherapy
Current Cancer Drug Targets The Heme Oxygenase/Biliverdin Reductase Pathway in Drug Research and Development
Current Drug Metabolism Cytoprotection and Immunomodulation in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents